Hennion & Walsh Asset Management Inc. Grows Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Hennion & Walsh Asset Management Inc. lifted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 6.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 78,095 shares of the biopharmaceutical company’s stock after buying an additional 4,806 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Ultragenyx Pharmaceutical were worth $4,338,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of RARE. International Assets Investment Management LLC grew its stake in Ultragenyx Pharmaceutical by 29,580.0% in the 3rd quarter. International Assets Investment Management LLC now owns 10,388 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 10,353 shares during the period. nVerses Capital LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 237.5% during the third quarter. nVerses Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 1,900 shares during the last quarter. CWM LLC grew its position in shares of Ultragenyx Pharmaceutical by 9,552.5% in the third quarter. CWM LLC now owns 21,332 shares of the biopharmaceutical company’s stock valued at $1,185,000 after purchasing an additional 21,111 shares during the period. Handelsbanken Fonder AB increased its stake in Ultragenyx Pharmaceutical by 15.0% in the third quarter. Handelsbanken Fonder AB now owns 24,523 shares of the biopharmaceutical company’s stock valued at $1,362,000 after purchasing an additional 3,200 shares during the last quarter. Finally, Maven Securities LTD increased its stake in Ultragenyx Pharmaceutical by 100.0% in the second quarter. Maven Securities LTD now owns 20,000 shares of the biopharmaceutical company’s stock valued at $822,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on RARE shares. The Goldman Sachs Group lifted their price target on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Canaccord Genuity Group restated a “buy” rating and issued a $111.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, July 23rd. TD Cowen increased their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday. Wells Fargo & Company boosted their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $88.29.

Insider Activity

In related news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total transaction of $1,003,400.00. Following the sale, the chief executive officer now owns 2,243,985 shares of the company’s stock, valued at $112,580,727.45. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $50.17, for a total transaction of $1,003,400.00. Following the completion of the sale, the chief executive officer now owns 2,243,985 shares of the company’s stock, valued at approximately $112,580,727.45. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,556 shares of company stock worth $2,519,367. 5.80% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $54.69 on Thursday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $60.37. The stock’s 50-day moving average is $55.97 and its two-hundred day moving average is $47.71. The stock has a market cap of $5.04 billion, a PE ratio of -7.49 and a beta of 0.57.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm had revenue of $147.03 million for the quarter, compared to analyst estimates of $123.20 million. During the same period in the previous year, the company posted ($2.25) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 35.7% on a year-over-year basis. On average, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.28 earnings per share for the current year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.